Key Takeaways
- Shares of Hims & Hers surged 7% following the announcement of a broadened collaboration with Eli Lilly
- Healthcare providers using the platform can now write prescriptions for Zepbound vials, KwikPen, and Foundayo through LillyDirect
- This partnership comes on the heels of a comparable agreement with Novo Nordisk signed in March for Wegovy distribution
- Leerink Partners analyst Michael Cherny raised concerns about Hims’ actual value proposition beyond serving as an access point
- Company CEO Andrew Dudum defended the strategy by drawing parallels to Netflix’s transformation in its formative years
Shares of Hims & Hers Health (HIMS) jumped 7% during Thursday’s trading session following the company’s announcement of an enhanced collaboration with pharmaceutical giant Eli Lilly, enabling direct prescriptions of weight loss medications to consumers.
Hims & Hers Health, Inc., HIMS
Medical professionals utilizing the Hims platform now have the capability to issue prescriptions for Zepbound vials, KwikPen devices, and Foundayo, which will be dispensed through the LillyDirect pharmacy network. This arrangement provides consumers with self-pay pricing options while enabling licensed healthcare providers to facilitate patient access to FDA-sanctioned GLP-1 treatments.
According to company statements, this partnership positions Hims to offer a “comprehensive suite of FDA-approved GLP-1 medications” through its digital platform. The service package includes clinical oversight and nutritional counseling delivered via a subscription-based framework.
This marks the telehealth company’s second significant GLP-1 partnership in recent weeks. Last month, Hims finalized an agreement with Novo Nordisk, which dismissed its patent infringement litigation against Hims in return for the company’s pledge to distribute branded Ozempic and Wegovy products through its network.
The Novo arrangement included certain concessions. Hims agreed to scale back its extensive compounding operations for GLP-1 medications as part of the settlement terms. The current Lilly partnership mirrors this approach.
The telehealth platform had established a significant foothold throughout 2024’s GLP-1 medication shortage period, when substantial demand coupled with constrained manufacturing capacity from pharmaceutical leaders created expansion opportunities. With supply chains now stabilized, market conditions have evolved.
Wall Street Analyst Questions Platform Value Proposition
Michael Cherny, an analyst with Leerink Partners, provided a cautious assessment of Thursday’s news. He recognized that Hims is broadening its service offerings and “functioning as a connector to provide additional alternatives” for patients seeking treatment.
However, Cherny noted it remains “unclear what specific value Hims delivers in this arrangement beyond serving as the initial access point for patients seeking Lilly medications.” This concern becomes increasingly relevant as the company transitions away from its compounding business model.
Company Leadership Defends Strategic Direction
CEO Andrew Dudum rejected characterizations that these pharmaceutical partnerships represent a strategic withdrawal. In his public remarks, he drew comparisons between Hims and Netflix during its transformation period.
“Netflix wasn’t merely distributing DVDs,” Dudum stated. “The company was fundamentally reshaping how consumers engaged with content by relentlessly focusing on selection and creating innovative delivery mechanisms for the products people desired most.”
Hims highlighted its comprehensive weight loss subscription program as proof of expanded value delivery. Subscribers receive round-the-clock care team availability, customized nutrition strategies, continuous clinical monitoring, and community engagement through the Hims & Hers Weight Loss network.
The company’s stated objective involves connecting users with appropriate treatment alternatives tailored to their specific medical backgrounds, personal preferences, and wellness objectives.
Market participants largely endorsed the CEO’s strategic narrative. HIMS shares maintained a 0.4% gain later in the trading day even as the broader S&P 500 index declined modestly. Eli Lilly shares remained essentially unchanged.
This Lilly collaboration represents the company’s most recent initiative to rebrand itself within the GLP-1 marketplace as a distribution platform facilitating medication access rather than functioning primarily as a compounder of alternative formulations.
